Myasthenia
gravis (MG) is a type of chronic autoimmune neuromuscular disease
which causes weakness in skeletal muscles in the arms and legs.
Double vision, facial paralysis, difficulty in walking, dropping of
eyelids, are symptoms of myasthenia gravis. This disease is diagnosed
by tests such as repetitive nerve stimulation test, blood test for
antibodies, edrophonium test, Computed Tomography (CT), and Magnetic
Resonance Imaging (MRI). Corticosteroids drugs (azathioprine, and
cyclosporine) and Acetylcholine esterase inhibitors (Edrophonium, and
Pyridostigmine) are used for the treatment of MG.
Get
In-Depth Sample Copy @
https://www.coherentmarketinsights.com/insight/request-sample/2625
Myasthenia
Gravis Treatment Market - Drivers
Consistent
research and development activities are expected to propel growth of
the myasthenia gravis treatment market. For instance, in October
2017, Alexion Pharmaceuticals, Inc. received approval from the U.S.
Food and Drug Administration for Soliris which contains eculizumab as
an active component. This drug is used for treatment of antibody
positive generalized myasthenia gravis, and it is also used in
treatment of paroxysmal nocturnal hemoglobinuria (PNH), atypical
hemolytic uremic syndrome (aHUS).
Increasing
number of clinical trials for treatment of myasthenia gravis are
expected to drive the myasthenia gravis treatment market growth. For
instance, in December 2017, Novartis AG initiated phase II clinical
trial of CFZ533 for treatment of severe myasthenia gravis. The main
function of CFZ533 is the modification of immune response by
deactivation of white blood cells. Hence, it is expected to help with
improvement and management of severe myasthenia gravis.
Myasthenia
Gravis Treatment Market - Regional Analysis
On
the basis of region, the global myasthenia gravis treatment market is
segmented into North America, Latin America, Europe, Asia Pacific,
Middle East, and Africa.
North
America is expected to hold a dominant position in the myasthenia
gravis treatment market over the forecast period. This is owing to
increasing incidence and prevalence of myasthenia gravis in the U.S.
For instance, in October 2018, according to the National Center for
Biotechnology Information (NCBI), incidence of myasthenia gravis was
around 5 to 30 cases per million person years and prevalence is
around 10 to 20 cases per 100,000 population in U.S.
Myasthenia
Gravis Treatment Market - Competitive Analysis
Key
players operating in the myasthenia gravis treatment market are
Novartis AG, Takeda Pharmaceutical Company Limited, Grifols, S.A.,
Valeant Pharmaceutical International, Inc. Alexion Pharmaceutical
Inc., F. Hoffmann-La Roche AG, CSL Behring, Baxter International,
Inc., Shire plc, and Avadel Pharmaceutical, PLC.
Myasthenia
Gravis Treatment Market – Taxonomy
By
Medications
-
Cholinesterase Inhibitors
-
Corticosteroids
-
Immunosuppressants
-
Plasmapheresis
-
Intravenous immunoglobulin (IVIg)
-
Monoclonal Antibody
By
Distribution Channels
-
Hospital Pharmacies
-
Retail Pharmacies
-
Online Pharmacies
Browse
Complete Research Report @
https://www.coherentmarketinsights.com/ongoing-insight/myasthenia-gravis-treatment-market-2625
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm
offering action-ready syndicated research reports, custom market
analysis, consulting services, and competitive analysis through
various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Contact
Us:
Mr.
Shah
Coherent
Market Insights
1001
4th Ave,
#3200
Seattle,
WA 98154
Tel:
+1-206-701-6702
No comments:
Post a Comment